SEC Form SC 13G/A filed by The Oncology Institute Inc. (Amendment)
$TOI
Medical/Nursing Services
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2024 | $2.50 | Buy | Jefferies |
| 9/14/2022 | $7.00 | Buy | Guggenheim |
| 8/15/2022 | $10.00 | Buy | Jefferies |
CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ:TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for acquisition targets, and establishing MSO platforms to deliver value-based oncology care nationwide. Bringing over 15 years of healthcare leadership, McInerney most recently served as the Chief Operations Officer of HOPCo Network Solutions, a subsidiary of Hea
CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI's success as a public company. Mr. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups. He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urolog
CERRITOS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today announced that, by mutual agreement with the Board of Directors, Brad Hively will step down as Chief Executive Officer effective June 30, 2023. Dr. Daniel Virnich, the current President of TOI, will become CEO. Mr. Hively will transition to the role of Vice Chairman of the Board of Directors. Dr. Daniel Virnich has been with The Oncology Institute since 2020, initially as Chief Operating Officer before being promoted to President. He joined TOI from DaVita where he was most recently Pres
CERRITOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2025 financial results after the market close on Wednesday, May 14, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and t
CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.Selling, general, and administrative expenses decreased 12% in Q4 2024 as compared to the prior year period, as a result of our ongoing efforts to streamline operations, improve efficiency, and o
CERRITOS, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its fourth quarter and full year 2024 financial results after the market close on Tuesday, March 25, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the
CERRITOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2025 financial results after the market close on Wednesday, May 14, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and t
CERRITOS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), a pioneer in value-based community oncology care, is proud to announce an enterprise-wide expansion of its strategic partnership with Helios Clinical Research, a nationally recognized research site network. This initiative builds upon a successful collaboration in Florida and reflects TOI's ongoing commitment to integrating clinical research into community oncology settings. "Expanding our research collaboration with Helios Clinical is a natural next step," said Daniel Virnich, MD, CEO at TOI. "They've proven to be a highly capable partner, helping us streamline study a
CERRITOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today proudly announced the launch of the Florida Oncology Network. This new fully delegated network will expand access to high-quality, coordinated cancer care for Florida residents. The Florida Oncology Network includes TOI Clinics and a robust panel of value-focused medical and radiation oncologists strategically located throughout the state. The network is designed to provide comprehensive cancer care that is accessible, affordable, and focused on outcomes for patients and payor partners.
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)
SCHEDULE 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
8-K - Oncology Institute, Inc. (0001799191) (Filer)
D - Oncology Institute, Inc. (0001799191) (Filer)
Jefferies resumed coverage of The Oncology Institute with a rating of Buy and set a new price target of $2.50
Guggenheim initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $7.00
Jefferies initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $10.00
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)